6 October 2025NewsBig PharmaMarisa Woutersen

Why AI drug discovery has an IP problem and what can be done?

Can AI tools raise the bar for inventiveness? And when algorithms become as productive as living systems, will they make their own outputs unpatentable? Industry experts unpick AI drug discovery’s biggest issues.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
25 September 2025   The firm’s Technology & Engineering team will be expanded with an expert in patent drafting, prosecution and opposition/defence work across AI, digital health and medical devices.
Asia
16 September 2025   From drug discovery to post-market surveillance, AI is rewriting the rules in pharma—and the patent system is struggling to keep up. At AIPPI’s World Congress 2025, Marisa Woutersen hears experts debate AI disclosure, inventive step, and inventorship.